Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracinostat + HMA in Refractory MDS
NCT01993641Phase 2Completed
- Sponsor
- Helsinn
- Start
- Dec 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pracinostat in myelodysplastic syndrome (MDS), sponsored by Helsinn. Primary endpoint: Clinical Improvement at 6 months. Started Dec 2013; status: completed.
02
Drugs
pracinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01993641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01993641.